# OnCo record elara (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/elara/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "elara", "NCT03568461" ;
  schema:name "ELARA"@en ;
  schema:alternateName "Tisagenlecleucel in follicular lymphoma"@en, "ELARA trial"@en ;
  schema:description "A single infusion of a patient's own reprogrammed immune cells cleared follicular lymphoma completely in about seven out of ten people who had already been through several treatments."@en ;
  schema:url <https://onco.cc/trials/elara/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03568461>, <https://doi.org/10.1038/s41591-021-01622-0> ;
  onco:status "positive" ;
  onco:tag "lymphoma-evidence" ;
  onco:phase "2" ;
  schema:startDate "2018-11-12" ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:drugs <https://onco.cc/drugs/tisagenlecleucel/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/complete-response/>, <https://onco.cc/terms/lymphoma-tx-pod24/>, <https://onco.cc/terms/lymphoma-tx-car-t-pathway/> ;
  onco:trials <https://onco.cc/trials/zuma-5/> ;
  onco:people <https://onco.cc/people/catherine-thieblemont/>, <https://onco.cc/people/martin-dreyling/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/>, <https://onco.cc/bottlenecks/b-global-access/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-elara-tisagenlecleucel-follicular-nat-med-2022/> .